Nisha Pandey

Health and Me

Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

<span>Eli Lilly</span> is rapidly expanding its presence in the global obesity treatment market. Its oral weight-loss drug <span>Foundayo</span> has received approval in China, becoming the first GLP-1 pill to get approved in the country.

In another development, its experimental drug combination of eloralintide and tirzepatide recently reported substantial weight loss in an early-stage clinical trial.

The developments come as pharmaceutical companies compete to develop more convenient treatments for obesity, including oral alternatives to injections and dual and triple-acting medicines.

<h2>Foundayo Weight Loss Pill Gets Approval In China</h2>

Also read: <a href="https://www.healthandme.com/health-wellness/world-diabetes-day-why-some-diabetes-patients-may-not-be-suitable-for-glp-1-treatment-experts-explain-article-156506659" data-type="tilCustomLink">World Diabetes Day: Why Some Diabetes Patients May Not Be Suitable For GLP-1 Treatment, Experts Explain</a>

RecnChina approved <span>orforglipron</span>, marketed as Foundayo in the US, making it the first GLP-1 medication in pill form approved for weight management in the country. Until now, Chinese regulators had authorised GLP-1 medicines for <a href="https://www.healthandme.com/health-wellness/natural-multigrain-immune-boosting-are-packaged-foods-really-healthy-for-kids-childrens-day-2026-article-156508651" data-type="tilCustomLink">obesity</a> treatment only as injections.

The approval gives <span>Lilly</span> an early advantage over its rival <span>Novo Nordisk</span>, which has also applied to market its oral <span>Wegovy</span> treatment in China.

Foundayo contains orforglipron, an oral, small-molecule GLP-1 receptor agonist. GLP-1 medicines mimic the action of a naturally occurring gut hormone involved in appetite regulation and blood sugar control.

Unlike injectables like Wegovy and <span>Zepbound</span>, Foundayo is taken once daily as a tablet. It can also be taken without restrictions on food and water intake, which may make it a more convenient option for people who prefer not to use injections.

In separate clinical trials, Foundayo produced an average weight reduction of approximately 11% over 72 weeks, while oral Wegovy achieved around 14% over 64 weeks. These results come from different studies.

<h2>Experimental Combination <span rel="noindex">EloraTZP</span> Shows Up To 23.3% Weight Loss</h2>

Also read: <a href="https://www.healthandme.com/health-news/stopping-mounjaro-zepbound-may-trigger-hallucinations-mania-other-psychiatric-symptoms-article-156496743" data-type="tilCustomLink">Stopping Mounjaro &amp; Zepbound May Trigger Hallucinations, Mania &amp; Other Psychiatric Symptoms</a>

In another development announced on November 14, Lilly reported promising Phase 2 results for EloraTZP, an experimental combination of eloralintide and <a href="https://www.healthandme.com/health-wellness/can-ozempic-mounjaro-drugs-protect-the-brain-what-a-new-review-found-article-156476288" data-type="tilCustomLink">tirzepatide</a>.

The combination brings together two medicines that act on appetite and metabolism differently. Tirzepatide, the active ingredient in Zepbound, activates <span>GIP</span> and GLP-1 receptors. Eloralintide is an investigational drug that acts on amylin receptors, which are involved in regulating appetite and feelings of fullness.

In adults with obesity and type 2 diabetes, participants receiving EloraTZP achieved weight loss of up to an average of 23.3% after 48 weeks. Their average starting weight was 232.4 pounds (approximately 105.4 kg). Up to 60% of participants no longer met the BMI criteria for obesity at the end of the study.

The combination also reduced the average blood glucose levels over approximately three months, by up to 2.9 percentage points. Up to 77% of participants achieved normal blood sugar levels, according to Lilly.

However, these are Phase 2 findings reported by Lilly, and the full trial results have not yet been published. Larger studies will be needed to establish the combination's safety and effectiveness in obesity treatment.

How to Enjoy Diwali on Ozempic & Mounjaro | Doctors Share GLP-1 Diet Tips

Lilly's latest update included findings from its Phase 3 SURMOUNT-ADOLESCENTS trials, which evaluated Zepbound in adolescents aged 12 to under 18 with obesity.

Participants experienced an average BMI reduction of 21.4% after 72 weeks. More than half no longer met the BMI criteria for obesity. They also reported improvements in aspects of quality of life due to weight reduction, including physical comfort and better body image.

Separately, the company reported Phase 3 findings for retatrutide, an experimental once-weekly medicine that activates three hormone receptors: GIP, GLP-1 and glucagon.

In trials involving adults with obesity, it reduced the severity of obstructive sleep apnoea and knee osteoarthritis pain. Retatrutide, an investigational drug, is not approved for general medical use.

Health Conditions A-Z

health

lillys-obesity-drugs-foundayo-becomes-first-glp-1-pill-approved-in-china-experimental-combo-shows-promise

foundayo

zepbound

lilly

wegovy

orforglipron

novo nordisk

eloratzp

eli lilly

91-of-indian-studies-spanning-50-years-link-air-pollution-to-diabetes-heart-disease-and-cancer

91% Of Indian Studies Spanning 50 Years Link Air Pollution To Diabetes, Heart Disease And Cancer

russias-mrna-cancer-vaccine-first-patient-completes-treatment-shows-no-new-tumours

Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Eli Lilly is rapidly expanding its presence in the global obesity treatment market. Its oral weight-loss drug Foundayo has received approval in China, becoming the first GLP-1 pill to get approved in the country. In another development, its experimental drug combination of eloralintide and tirzepatide recently reported substantial weight loss in an early-stage clinical trial.The developments come as pharmaceutical companies compete to develop more convenient treatments for obesity, including oral alternatives to injections and dual and triple-acting medicines.Foundayo Weight Loss Pill Gets Approval In China Also read: World Diabetes Day: Why Some Diabetes Patients May Not Be Suitable For GLP-1 Treatment, Experts ExplainRecnChina approved orforglipron, marketed as Foundayo in the US, making it the first GLP-1 medication in pill form approved for weight management in the country. Until now, Chinese regulators had authorised GLP-1 medicines for obesity treatment only as injections.The approval gives Lilly an early advantage over its rival Novo Nordisk, which has also applied to market its oral Wegovy treatment in China. Foundayo contains orforglipron, an oral, small-molecule GLP-1 receptor agonist. GLP-1 medicines mimic the action of a naturally occurring gut hormone involved in appetite regulation and blood sugar control.Unlike injectables like Wegovy and Zepbound, Foundayo is taken once daily as a tablet. It can also be taken without restrictions on food and water intake, which may make it a more convenient option for people who prefer not to use injections.In separate clinical trials, Foundayo produced an average weight reduction of approximately 11% over 72 weeks, while oral Wegovy achieved around 14% over 64 weeks. These results come from different studies.Experimental Combination EloraTZP Shows Up To 23.3% Weight LossAlso read: Stopping Mounjaro & Zepbound May Trigger Hallucinations, Mania & Other Psychiatric SymptomsIn another development announced on November 14, Lilly reported promising Phase 2 results for EloraTZP, an experimental combination of eloralintide and tirzepatide.The combination brings together two medicines that act on appetite and metabolism differently. Tirzepatide, the active ingredient in Zepbound, activates GIP and GLP-1 receptors. Eloralintide is an investigational drug that acts on amylin receptors, which are involved in regulating appetite and feelings of fullness.In adults with obesity and type 2 diabetes, participants receiving EloraTZP achieved weight loss of up to an average of 23.3% after 48 weeks. Their average starting weight was 232.4 pounds (approximately 105.4 kg). Up to 60% of participants no longer met the BMI criteria for obesity at the end of the study.The combination also reduced the average blood glucose levels over approximately three months, by up to 2.9 percentage points. Up to 77% of participants achieved normal blood sugar levels, according to Lilly.However, these are Phase 2 findings reported by Lilly, and the full trial results have not yet been published. Larger studies will be needed to establish the combination's safety and effectiveness in obesity treatment.More Updates From Lilly       Lilly's latest update included findings from its Phase 3 SURMOUNT-ADOLESCENTS trials, which evaluated Zepbound in adolescents aged 12 to under 18 with obesity.Participants experienced an average BMI reduction of 21.4% after 72 weeks. More than half no longer met the BMI criteria for obesity. They also reported improvements in aspects of quality of life due to weight reduction, including physical comfort and better body image.Separately, the company reported Phase 3 findings for retatrutide, an experimental once-weekly medicine that activates three hormone receptors: GIP, GLP-1 and glucagon. In trials involving adults with obesity, it reduced the severity of obstructive sleep apnoea and knee osteoarthritis pain. Retatrutide, an investigational drug, is not approved for general medical use.

lilly's obesity drugs: foundayo becomes first glp-1 pill approved in china, experimental combo shows promise

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

91% Of Indian Studies Spanning 50 Years Link Air Pollution To Diabetes, Heart Disease And Cancer

Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours

AIIMS Delhi Performs India's First Open Fetal Surgery To Repair Spina Bifida

Health Conditions A-Z

Lilly's Obesity Drugs: Foundayo Becomes First GLP-1 Pill Approved In China, Experimental Combo Shows Promise

91% Of Indian Studies Spanning 50 Years Link Air Pollution To Diabetes, Heart Disease And Cancer

Russia's mRNA Cancer Vaccine: First Patient With Melanoma Completes Treatment, Shows No New Tumours